During the Phase 1 part, different arms may be opened to test JCAR017 in combination with combination agent(s). Within each arm, different doses and schedules of JCAR017 and the combination agent(s) may be tested in several cohorts and subcohorts per arm. During the Phase 2 part of the study, the expansion of any dose level and schedule that has been shown to be safe may occur.